
iBio (IBIO) Stock Forecast & Price Target
iBio (IBIO) Analyst Ratings
Bulls say
iBio is a promising biotech company that utilizes AI technology to minimize downstream development risks and optimize their precision antibodies. The company has shown promising preclinical results and recently transitioned to clinical-stage, with their first drug candidate, IBIO-600, entering human trials. The company's strong pipeline and potential for future revenue have resulted in a 12-month price target of $5 per share. However, as a development stage company, there are inherent risks involved, including the need to raise additional funds and potential intellectual property infringement.
Bears say
iBio is a preclinical biotech company with a negative outlook due to potential competition, challenges with intellectual property protection, and the possibility of future dilution for stockholders. Despite their current orphan drug status and plans for niche market sales, the company may face difficulties in securing external financing and navigating the complex clinical and regulatory landscape.
This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares